Still, the selection of thermostable mutations is not a standard process.
The gold standard for defining driver mutations is not only clonal outgrowth, but that the profile of mutations observed is significantly skewed from the profile of background passenger mutations.
The identification of stabilizing mutations is not trivial, and this review will focus on the methods that have been used to identify stabilized membrane proteins, including alanine scanning and screening, directed evolution and computational design.
So far, the mechanism for the effects of ATP1A2 mutations is not clear.
Genotype-phenotype correlation in FHM caused by ATP1A2 mutations is not well defined.
Unfortunately, this variability particularly caused by somatic mutations is not always easy to discern.
Testing for MTHFR SNPs, what Lynch is calling "mutations," is not recommended by any professional medical organization.
All levels of gene expression require coordination to optimize available resources, but how global gene expression drives cancers or responds to disrupting oncogenic mutations is not understood.
The distribution of the fitness effects of silent mutations is not different from that of amino acid altering mutations.
Though less specific and often associated with partial resistance only, disease resistance through antimicrobial compounds has been observed to be durable, since resistance breakdown through deleterious Avr mutations is not possible.
Additionally, the genotypic presence of mutations is not necessarily associated with clinical resistance.
